Nicotinamide adenine dinucleotide (NAD) supplements have gained popularity for their purported anti-ageing and energy-boosting properties, but concerns have emerged about their safety, particularly regarding cancer risk. NAD is a vital coenzyme involved in cellular metabolism, and its levels naturally decline with age. People typically take NAD precursors such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) to boost NAD+ levels. However, questions about whether elevating NAD+ might inadvertently fuel cancer cell growth have prompted scientific investigation. This article examines the current evidence on NAD supplementation and cancer risk, explores safety considerations, and provides guidance on when to consult your GP.

What Is NAD and Why Do People Take It?

Nicotinamide adenine dinucleotide (NAD) is a coenzyme found in every living cell in the human body. It plays a fundamental role in cellular metabolism, acting as a crucial electron carrier in the processes that convert nutrients into energy. NAD exists in two forms: NAD+ (oxidised) and NADH (reduced), and the balance between these forms is essential for maintaining cellular health and function.

As we age, NAD+ levels naturally decline in tissues throughout the body. This observation has led to interest in NAD supplementation. People typically take NAD precursors—such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN)—rather than NAD itself, as these compounds are believed to be more readily absorbed. It's important to note that in the UK and EU, nicotinamide riboside chloride is authorised as a novel food with specific maximum intake limits, while NMN is not currently authorised as a novel food and should not be marketed as a food supplement.

Common reasons people use NAD supplements include:

• Attempting to boost energy levels and reduce fatigue

• Supporting cognitive function and mental clarity

• Promoting healthy ageing and longevity

• Enhancing athletic performance and recovery

• Supporting metabolic health

However, it's important to understand that robust, long-term human evidence for these potential benefits remains limited and inconclusive, particularly for NR and NMN supplements. While NAD is essential for life and cellular function, the effects of supplemental doses may differ from the body's natural NAD metabolism.

Current Evidence on NAD and Cancer Risk

The relationship between NAD supplementation and cancer is complex and remains an active area of scientific investigation. Currently, there is no official link established between NAD supplements and cancer causation in humans. However, the theoretical concerns warrant careful consideration and ongoing research.

Cancer cells, like all rapidly dividing cells, require substantial amounts of energy and have elevated metabolic demands. NAD+ is essential for these metabolic processes, and some laboratory studies have shown that cancer cells can utilise increased NAD+ availability to support their growth. This has led researchers to question whether boosting NAD+ levels through supplementation might inadvertently provide fuel for existing malignancies or pre-cancerous cells.

Key points from current research:

• Preclinical studies (in cell cultures and animal models) have produced mixed results, with some suggesting NAD+ elevation may support tumour growth whilst others indicate potential protective effects

• The enzyme CD38, which degrades NAD+, is elevated in certain types of cancer (such as chronic lymphocytic leukaemia and multiple myeloma), suggesting some tumours may have altered NAD metabolism

• Some preclinical research suggests NAD+ metabolism might influence cancer treatment responses, but human clinical evidence is currently lacking

• No large-scale, long-term human trials have definitively established causation between NAD supplementation and cancer incidence

In the UK, food supplements are regulated by the Food Standards Agency (FSA), not the Medicines and Healthcare products Regulatory Agency (MHRA) unless medicinal claims are made. Individuals with cancer or at high risk should consult their GP or oncology team before using NAD supplements, as the evidence base continues to evolve.

Safety Considerations for NAD Supplements

When considering NAD supplementation, several important safety factors merit attention. Whilst short-term studies have generally found nicotinamide riboside to be well-tolerated, long-term safety data in humans remains limited.

Common side effects reported with NAD precursors include:

• Mild gastrointestinal symptoms (nausea, bloating, diarrhoea)

• Headache

• Fatigue or sleep disturbances

Note that flushing is more commonly associated with nicotinic acid (a form of vitamin B3) rather than NR or NMN. Side effects are typically dose-dependent and resolve when supplementation is discontinued. Very high doses of nicotinamide can potentially cause liver enzyme elevations.

Individuals who should exercise particular caution include:

• Those with a personal or strong family history of cancer

• People currently undergoing cancer treatment or in remission

• Individuals with pre-existing liver or kidney conditions

• Pregnant or breastfeeding women (due to insufficient safety data)

• Those taking medications that affect NAD metabolism

The European Food Safety Authority (EFSA) has established tolerable upper intake levels for nicotinamide, and authorised nicotinamide riboside chloride has specific maximum daily intake limits. The quality and purity of supplements can vary considerably between manufacturers, as food supplements are not subject to the same rigorous testing as licensed medicines. If you experience any adverse effects from supplements, report them through the MHRA Yellow Card scheme.

It is worth noting that maintaining NAD levels through lifestyle measures—including regular physical activity, a balanced diet rich in B vitamins (found in foods like milk, fish, and mushrooms), adequate sleep, and avoiding excessive alcohol consumption—may offer benefits without the uncertainties associated with high-dose supplementation. Intravenous NAD+ infusions are not licensed medicines in the UK and carry additional risks.

When to Speak with Your GP About NAD

Given the evolving evidence base and theoretical concerns surrounding NAD supplementation, consulting your GP before starting these supplements is advisable, particularly in certain circumstances.

You should definitely speak with your GP before taking NAD supplements if you:

• Have been diagnosed with cancer or are currently receiving cancer treatment (also discuss with your oncology team)

• Are in remission from cancer

• Have a strong family history of cancer or known genetic predisposition

• Are taking any prescribed medications, as interactions may occur

• Have existing liver, kidney, or metabolic conditions

• Are pregnant, planning pregnancy, or breastfeeding

• Experience any unusual symptoms after starting supplementation

During your consultation, your GP can assess your individual risk factors and help you weigh the potential benefits against theoretical risks. They may consider whether any underlying health concerns might be better addressed through evidence-based interventions rather than supplementation.

Seek urgent medical attention if you experience:

• Unexplained weight loss

• Persistent fatigue not improved by rest

• New lumps or swellings

• Changes in bowel or bladder habits

• Unusual bleeding or bruising

• Persistent pain without clear cause

These symptoms warrant investigation regardless of supplement use, as they may indicate conditions requiring prompt medical assessment. Call NHS 111 for urgent advice or 999 in life-threatening emergencies.

Your GP can also direct you to reliable, evidence-based information sources such as the NHS website and Cancer Research UK, which provide trustworthy information about cancer prevention and risk factors. Remember that whilst maintaining optimal nutrition is important, no supplement can substitute for proven cancer prevention strategies, including not smoking, maintaining a healthy weight, limiting alcohol intake, staying physically active, and attending recommended screening programmes.

Frequently Asked Questions